TrialJournal of hematology & oncology2018

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.

Meletios Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.